Etanercept Reduces Symptoms and Severity of Psoriasis After Cessation of Cyclosporine Therapy: Results of the SCORE Study

Authors

  • Giuseppe Micali
  • Dagmar Wilsmann-Theis
  • Lotus Mallbris
  • Gaia Gallo
  • Valentina Marino
  • Yves Brault
  • Jean-Michel Germain

DOI:

https://doi.org/10.2340/00015555-1845

Keywords:

psoriasis, tumour necrosis factor, etanercept, cyclosporine

Abstract

Cyclosporine is an established therapy for psoriasis that provides rapid relief of symptoms but has long-term toxic side effects. The objective of this study was to demonstrate the efficacy of etanercept as replacement therapy for cyclosporine in patients with moderate-to-severe plaque psoriasis. Patients with plaque psoriasis were given cyclosporine 5 mg/kg/day until achievement of PASI50 at which point cyclosporine was tapered to 0 over 6 weeks. At week 6, patients were randomised (1:1) to receive etanercept (50 mg/week) or placebo for an additional 24 weeks. Patients in the etanercept group (n=58) experienced a reduction of –1.1 in mean PASI score (p=0.233 vs. cyclosporine) at week 30; patients in the placebo group (n=62) had mean PASI increase of 3.7 (p<0.001 vs. cyclosporine). The incidence of patients reporting any adverse events was not significant between groups (77% etanercept, 74% placebo; p=0.675). Etanercept demonstrated higher efficacy and good tolerability as replacement therapy for cyclosporine in plaque psoriasis.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2014-06-03

How to Cite

Micali, G., Wilsmann-Theis, D., Mallbris, L., Gallo, G., Marino, V., Brault, Y., & Germain, J.-M. (2014). Etanercept Reduces Symptoms and Severity of Psoriasis After Cessation of Cyclosporine Therapy: Results of the SCORE Study. Acta Dermato-Venereologica, 95(1), 57–61. https://doi.org/10.2340/00015555-1845

Issue

Section

Articles